Navigation Links
Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Date:9/7/2007

BALTIMORE, Sept. 7 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Betsy Van Parijs, M.D., Ph.D. to Senior Vice President, Clinical Development and Medical Affairs. In this role, Dr. Van Parijs will be responsible for leading Alba's clinical development strategy and program execution through product approval and commercialization. Dr. Van Parijs will also serve as a member of Alba's executive management leadership team.

"We are very pleased to announce that Dr. Van Parijs is joining Alba in this critical leadership role. Betsy is an accomplished executive with extensive experience in clinical development including the development, execution and validation of a patient-reported outcomes (PRO) instrument as a new primary efficacy endpoint for clinical trials," said Blake Paterson, M.D., Alba's Chief Executive Officer. "Her leadership in our efforts to validate the celiac disease activity rating score in our upcoming Phase II clinical trials will be essential for the success of AT-1001 as the first drug for celiac disease," added Dr. Paterson.

"Alba has a singular approach to the treatment of seemingly diverse clinical syndromes. Its discovery engine and clinical path offer the promise of redefining the pathogenesis and treatment of certain autoimmune diseases. I am delighted to join such a dedicated and innovative organization," said Dr. Van Parijs.

Prior to joining Alba, Dr. Van Parijs held senior level positions in clinical development (phases II-IV) and medical affairs at two multinational pharmaceutical companies. From 2003 to 2007, Dr. Van Parijs served as Senior Director, Clinical Development and Medical Affairs in the Infectious Diseases Center (Anti-Infectives) at GlaxoSmithKline (GSK) where she was responsible for directing the clinical sections of regulatory submissions, defining and implementing later phase clinical strategy for Anti-Infectives in the pipeline, and for medical affairs, including promotional review activities of the late phase group focusing on marketed products. Dr. Van Parijs also led the development, execution and validation of a new primary efficacy endpoint for clinical trials in acute exacerbations of COPD (AECOPD). From 2001-2002, Dr. Van Parijs served as Director, Global Medical Affairs (Vaccines) at Wyeth. She also led the clinical development through to submission and market support of some vaccines for GSK earlier, enhancing her experience in the application of clinical immunology to the clinical development, submission and commercialization process.

Dr. Van Parijs holds a Ph.D. in Neuroscience and earned her M.D. from Christian Medical College, Vellore, University of Madras in Tamil Nadu, India. She has published numerous research and clinical development articles and has received various honors including GSK's R&D Silver Award for Leadership in Developing a New Patient-Reported Outcomes Instrument for AECOPD.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to the development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory diseases, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body. Alba's lead compound, AT-1001, is targeted toward the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes.

Contact: Dr. Bernard McDonald

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Website: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Sharon Ethanol appoints operations director
3. Kyron appoints former AMA chairman to board
4. Brady appoints GE efficiency expert as CTO
5. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
6. Johnson Controls appoints Roell to head EOC
7. SecurePipe appoints two senior execs
8. Milwaukees PointOne appoints new president and CEO
9. Third Wave appoints new chairman
10. Midwest Venture Summit disappoints; Cato grades Midwest governors
11. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016 On Thursday, February 11, ... for community, health and disaster services, and the ... to enhance care coordination and service delivery for the ... need and to better connect service providers to the ... San Diego has handled more than ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... JUNCTION, N.J. , Feb. 4, 2016 /PRNewswire/ ... care immunotherapy leader commercializing its flagship CytoSorb® blood ... cardiac surgery patients around the world, announced that ... will present at the Source Capital Group,s 2016 ... and update on the company.  ...
Breaking Biology Technology:
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):